IGC Pharma Begins Patient Enrollment for Phase 2 IGC-AD1 Trial at Neurostudies
IGC Pharma, Inc. (NYSE American: IGC) has launched a Phase 2 clinical trial to study IGC-AD1 as a potential treatment for agitation in Alzheimer's disease. The trial is being conducted at Neurostudies, Inc. in Port Charlotte, Florida. Neurostudies has enrolled its first two patients, marking a significant step in IGC Pharma's efforts to address Alzheimer's-related agitation.
IGC-AD1, the focus of the trial, is a partial CB1r agonist with properties that combat neuroinflammation and inhibit inflammasomes. It includes low doses of Tetrahydrocannabinol (THC), the main psychoactive component of Cannabis. This formulation is unique as it is the first THC-based drug undergoing a formal Phase 2 trial for Alzheimer's-related agitation.
The trial at Neurostudies is led by Dr. Liliana Montoya, Principal Investigator, and Dr. George Li, Sub-Investigator. Neurostudies brings over 20 years of clinical research experience. The enrollment of the first two patients underscores IGC Pharma's strategy to enhance shareholder value through innovation in Alzheimer's treatment. The company aims to address the unmet medical needs related to Alzheimer's agitation through these clinical trials.
Ram Mukunda, CEO of IGC Pharma, expressed optimism about the trial, stating that the enrollment at Neurostudies is a pivotal step in bringing IGC-AD1 to market. Mukunda emphasized that this development aligns with the company's strategic approach to clinical research and its commitment to innovation and scientific rigor. He is hopeful that the collaboration with Neurostudies will lead to significant advancements in Alzheimer's care.
Dr. Liliana Montoya highlighted the challenges that agitation poses for Alzheimer's patients and their families. She affirmed that leading the Phase 2 trial at Neurostudies demonstrates their dedication to rigorous scientific research and improving patient care. The collaboration with IGC Pharma aims to translate innovative scientific research into real-world benefits for those affected by Alzheimer's.
IGC Pharma plans to expand the trial to include 11 additional sites in the U.S. and Canada, aiming to enroll a total of 146 patients. Half of these patients will receive IGC-AD1, while the other half will receive a placebo.
IGC Pharma, Inc. is a company committed to developing treatments for Alzheimer's disease. They have a pipeline of five drug candidates targeting various aspects of the disease, including neuroinflammation, Aβ plaques, and neurofibrillary tangles. IGC-AD1 is undergoing Phase 2 trials for Alzheimer's-related agitation, while other candidates like TGR-63 and IGC-M3 are in preclinical stages, targeting the disease's progression and early-stage symptoms. Additionally, IGC Pharma is exploring the use of artificial intelligence to enhance Alzheimer's research, including optimizing clinical trials and early detection.
Neurostudies, Inc., located in Port Charlotte, Florida, is a leading clinical research center specializing in neurological disorders. It is managed by Dr. Liliana Montoya and Dr. George Li, both renowned neurologists dedicated to advancing clinical research to improve patient outcomes.
This announcement by IGC Pharma marks a significant advancement in Alzheimer's research, focusing on addressing the critical issue of agitation in Alzheimer's patients. The company's strategic initiatives and collaboration with Neurostudies highlight its commitment to transforming Alzheimer's treatment through innovative and rigorous scientific research. As the trial progresses, IGC Pharma remains focused on their mission to deliver groundbreaking therapies for Alzheimer's disease.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
